IDEXX Laboratories' Stock Performance Lags Behind Broader Market IDEXX Laboratories has underperformed the Nasdaq Composite over the past year, with shares down nearly 25% from their 52-week high. Despite strong Q4 earnings, the company faces challenges, including slowing growth in its Companion Animal Group and weak veterinary clinic visits, impacting investor sentiment.678